Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
Sara N LevintowKate K OrrothAlexander BreskinAndrew S ParkJose H Flores ArredondoPaul DluzniewskiAnn Marie NavarHenrik T SørensenM Alan BrookhartPublished in: Pharmacoepidemiology and drug safety (2021)
Observed associations suggest lower frailty and potentially greater health-seeking behaviors among PCSK9i initiators, particularly those with a recent ASCVD diagnosis, with the potential to bias real-world analyses of treatment effectiveness. This article is protected by copyright. All rights reserved.
Keyphrases
- end stage renal disease
- mental health
- public health
- healthcare
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- type diabetes
- climate change
- health information
- human health
- fatty acid
- adipose tissue
- social media
- insulin resistance
- combination therapy
- glycemic control
- weight loss
- health promotion
- community dwelling
- smoking cessation